Series B · Biotech
CREATE Medicines: Series B
Develops in vivo immune programming platform for scalable, repeat-dose immunotherapies
Funding history
Series B · This round$122M
Loading rounds…
Develops in vivo immune programming platform for scalable, repeat-dose immunotherapies